Riktkurs.nu
EN | SV
ByggmaxMid CapCamurus
Stockholm Stock Exchange | Mid Cap
Calliditas
+138.99%
Latest
+83.65%
3 months
Bryan GarnierCarnegieSEBKepler CheuvreuxPareto SecuritiesCiti Investment ResearchKempenSEB Equities

Price Targets For Calliditas

AnalystPrice TargetDateUpside
Bryan Garnier190 SEKSep 21
+138.99%
Carnegie133 SEKAug 19
SEB115 SEKJul 27
Kepler Cheuvreux140 SEKJun 16
Pareto Securities300 SEKJun 2
Citi Investment Research384 SEKDec -21
Kempen320 SEKDec -21
SEB Equities75 SEKNov -21

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas

The information on Riktkurs.nu is for general information purposes only. Riktkurs.nu makes no guarantees of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to Riktkurs.nu or the information, products, services, or related information on Riktkurs.nu for any purpose. The recipient is recommended to complete his or her decision basis with the material deemed necessary. We reserve us for all types of errors as well as any malfunctions of the website. The information on Riktkurs.nu should not be seen as a recommendation to buy or sell a security.
© Riktkurs.nu 2022